Article

In Silico Evaluation of Ten Monoclonal Antibodies Neutralization Power of SARS-CoV-2 Variants EG.5, BA.2.86 and JN.1

2024-08-19

Abstract excerpt

The current globally dominant SARS-CoV-2 variants are showing immune escape and reduced susceptibility to antiviral drugs. Therefore, agencies responsible for drug evaluation and regulation such as the FDA and EMA are revising their emergency authorization use of several COVID-19 neutralizing antibodies. These MAbs proved to be unlikely effective against new variants especially Omicron descendants and several phar...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: fef60ae1-5cbc-5770-8a50-3176fd26463d
DOI: 10.20944/preprints202408.1340.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

In Silico Evaluation of Ten Monoclonal Antibodies Neutralization Power of SARS-CoV-2 Variants EG.5, BA.2.86 and JN.1DOI 10.20944/preprints202408.1340.v1Read

In silico evaluation of ten monoclonal antibodies neutralization power of SARS-CoV-2 variants EG.5, BA.2.86 and JN.1Semantic proximity Read

In silico evaluation of ten monoclonal antibodies neutralization power of SARS-CoV-2 variants EG.5 and BA.2.86Semantic proximity Read

Antibody drugs targeting SARS-CoV-2: Time for a rethink?Semantic proximity Read

Atlas of currently available human neutralizing antibodies against SARS-CoV-2 and escape by Omicron sub-variants BA.1/BA.1.1/BA.2/BA.3Semantic proximity Read

A novel consensus‐based computational pipeline for screening of antibody therapeutics for efficacy against SARS‐CoV‐2 variants of concern including Omicron variantSemantic proximity Read

A novel consensus-based computational pipeline for rapid screening of antibody therapeutics for efficacy against SARS-CoV-2 variants of concern including omicron variantSemantic proximity Read

Predicting the immune escape of SARS-CoV-2 neutralizing antibodies upon mutation.Semantic proximity Read

Application of an integrated computational antibody engineering platform to design SARS-CoV-2 neutralizersSemantic proximity Read

In Silico Analyses on the Comparative Potential of Therapeutic Human Monoclonal Antibodies Against Newly Emerged SARS-CoV-2 Variants Bearing Mutant Spike ProteinSemantic proximity Read

Atlas of Currently-Available Human MAbs and Escape to Newly-Emerging Omicron BA.1/BA.1.1/BA.2/BA.3Semantic proximity Read

Differences between Omicron SARS-CoV-2 RBD and other variants in their ability to interact with cell receptors and monoclonal antibodiesSemantic proximity Read

Impact of BA.1, BA.2, and BA.4/BA.5 Omicron mutations on therapeutic monoclonal antibodies.Semantic proximity Read